<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35807341</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>13</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>25</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Enzymatic Biotransformation of Gypenoside XLIX into Gylongiposide I and Their Antiviral Roles against Enterovirus 71 In Vitro.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4094</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules27134094</ELocationID><Abstract><AbstractText>Biotransformation of specific saponins in the valuable medical plants to increase their bioavailability and pharmaceutical activities has attracted more and more attention. A gene encoding a thermophilic glycoside hydrolase from <i>Fervidobaterium pennivorans</i> DSM9078 was cloned and expressed in <i>Escherichia coli</i>. The purified recombinant enzyme, exhibiting endoglucanase cellulase activity, was used to transform gypenoside XLIX into gylongiposide I via highly selective and efficient hydrolysis of the glucose moiety linked to the C21 position in gypenoside XLIX. Under the optimal reaction conditions for large scale production of gylongiposide I, 35 g gypenoside XLIX was transformed by using 20 g crude enzyme at pH 6.0 and 80 &#xb0;C for 4 h with a molar yield of 100%. Finally, 11.51 g of gylongiposide I was purified using a silica gel column with 91.84% chromatographic purity. Furthermore, inhibitory activities of gypenoside XLIX and gylongiposide I against Enterovirus 71 (EV71) were investigated. Importantly, the EC<sub>50</sub> of gypenoside XLIX and gylongiposide I calculated from viral titers in supernatants was 3.53 &#x3bc;M and 1.53 &#x3bc;M, respectively. Moreover, the transformed product gylongiposide I has better anti-EV71 activity than the glycosylated precursor. In conclusion, this enzymatic method would be useful in the large-scale production of gylongiposide I, which would be a novel potent anti-EV71 candidate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Huanxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 130117, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Wenbo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun 130117, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 130117, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Kailu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 130117, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 130117, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 130117, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 130117, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20210204098YY and 20200201093JC</GrantID><Agency>Science and Technology Development Plan Project of Jilin Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C517623">3-((O-6-deoxymannopyranosyl-1-2-O-(xylopyranosyl-1-3)arabinopyranosyl)oxy)-21-glucopyranosyloxy-20-hydroxydammar-24-en-19-al</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C442845">gylongiposide I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012503">Saponins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001711" MajorTopicYN="N">Biotransformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029774" MajorTopicYN="N">Gynostemma</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012503" MajorTopicYN="Y">Saponins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014315" MajorTopicYN="N">Triterpenes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">Gynostemma pentaphyllum (Thunb.) Makino</Keyword><Keyword MajorTopicYN="N">biotransformation</Keyword><Keyword MajorTopicYN="N">gylongiposide I</Keyword><Keyword MajorTopicYN="N">gypenoside XLIX</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35807341</ArticleId><ArticleId IdType="pmc">PMC9268165</ArticleId><ArticleId IdType="doi">10.3390/molecules27134094</ArticleId><ArticleId IdType="pii">molecules27134094</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cui W.Y., Jin Y., Liu H., Zu M.L., Zhai X.F., Yang C., Gu Y.L., Cheng Y., Piao X.L. Dammarane-type saponins from Gynostemma pentaphyllum and their cytotoxicities. Nat. Prod. Res. 2021;35:4433&#x2013;4441. doi: 10.1080/14786419.2020.1723093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14786419.2020.1723093</ArticleId><ArticleId IdType="pubmed">32037885</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Liu H., Lv C., Du J., Lian F., Zhang S., Wang Z., Zeng Y. Gypenoside-Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer. BioMed Res. Int. 2022;2022:9304552. doi: 10.1155/2022/9304552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/9304552</ArticleId><ArticleId IdType="pmc">PMC8984741</ArticleId><ArticleId IdType="pubmed">35402614</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Yang Q., Dong B., Qi C., Yang T., Li M., He S., Liu B., Wu J. Gypenosides Attenuate Pulmonary Fibrosis by Inhibiting the AKT/mTOR/c-Myc Pathway. Front. Pharmacol. 2021;12:806312. doi: 10.3389/fphar.2021.806312.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.806312</ArticleId><ArticleId IdType="pmc">PMC8795913</ArticleId><ArticleId IdType="pubmed">35095515</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G., Zhang J., Wang S., Wang J., Wang J., Zhu Y., Wang J. Gypenoside Inhibits Bovine Viral Diarrhea Virus Replication by Interfering with Viral Attachment and Internalization and Activating Apoptosis of Infected Cells. Viruses. 2021;13:1810. doi: 10.3390/v13091810.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13091810</ArticleId><ArticleId IdType="pmc">PMC8473207</ArticleId><ArticleId IdType="pubmed">34578391</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K., Zhang H., Luo Y., Zhang J., Wang M., Liao P., Cao L., Guo P., Sun G., Sun X. Gypenoside XVII Prevents Atherosclerosis by Attenuating Endothelial Apoptosis and Oxidative Stress: Insight into the ER&#x3b1;-Mediated PI3K/Akt Pathway. Int. J. Mol. Sci. 2017;18:77. doi: 10.3390/ijms18020077.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18020077</ArticleId><ArticleId IdType="pmc">PMC5343768</ArticleId><ArticleId IdType="pubmed">28208754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.H., Jung J.I., Jeon Y.E., Kim S.M., Oh T.K., Lee J., Moon J.M., Kim T.Y., Kim E.J. Gynostemma pentaphyllum extract and Gypenoside L enhance skeletal muscle differentiation and mitochondrial metabolism by activating the PGC-1&#x3b1; pathway in C2C12 myotubes. Nutr. Res. Pract. 2022;16:14&#x2013;32. doi: 10.4162/nrp.2022.16.1.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.4162/nrp.2022.16.1.14</ArticleId><ArticleId IdType="pmc">PMC8784263</ArticleId><ArticleId IdType="pubmed">35116125</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Chen X., Zong B., Yuan H., Wang Z., Wei Y., Wang X., Liu G., Zhang J., Li S., et al. Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation. J. Cell Mol. Med. 2018;22:4437&#x2013;4448. doi: 10.1111/jcmm.13743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13743</ArticleId><ArticleId IdType="pmc">PMC6111804</ArticleId><ArticleId IdType="pubmed">29993180</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L.H., Zhao Y.Y., Bai M., Geliebter D., Geliebter J., Tiwari R., He H.J., Wang Z.Z., Jia X.Y., Li J., et al. Mechanistic Studies of Gypenosides in Microglial State Transition and its Implications in Depression-Like Behaviors: Role of TLR4/MyD88/NF-&#x3ba;B Signaling. Front. Pharmacol. 2022;13:838261. doi: 10.3389/fphar.2022.838261.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.838261</ArticleId><ArticleId IdType="pmc">PMC8973912</ArticleId><ArticleId IdType="pubmed">35370734</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen N.H., Ha T.K.Q., Yang J.L., Pham H.T.T., Oh W.K. Triterpenoids from the genus Gynostemma: Chemistry and pharmacological activities. J. Ethnopharmacol. 2021;268:113574. doi: 10.1016/j.jep.2020.113574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2020.113574</ArticleId><ArticleId IdType="pubmed">33186700</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y., Zheng Z., Ming Y., Lin M., Chen L., Huang W., Xiao J., Lin H. Gynosaponin TN-1 producing from the enzymatic conversion of gypenoside XLVI by naringinase and its cytotoxicity on hepatoma cell lines. Food Chem. Toxicol. 2018;119:161&#x2013;168. doi: 10.1016/j.fct.2018.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2018.05.007</ArticleId><ArticleId IdType="pubmed">29751078</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui C.H., Kim D.J., Jung S.C., Kim S.C., Im W.T. Enhanced Production of Gypenoside LXXV Using a Novel Ginsenoside-Transforming &#x3b2;-Glucosidase from Ginseng-Cultivating Soil Bacteria and Its Anti-Cancer Property. Molecules. 2017;22:844. doi: 10.3390/molecules22050844.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22050844</ArticleId><ArticleId IdType="pmc">PMC6153937</ArticleId><ArticleId IdType="pubmed">28534845</ArticleId></ArticleIdList></Reference><Reference><Citation>Park C.S., Yoo M.H., Noh K.H., Oh D.K. Biotransformation of ginsenosides by hydrolyzing the sugar moieties of ginsenosides using microbial glycosidases. Appl. Microbiol. Biotechnol. 2010;87:9&#x2013;19. doi: 10.1007/s00253-010-2567-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-010-2567-6</ArticleId><ArticleId IdType="pubmed">20376631</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong F.L., Dong W.W., Wu S., Jiang J., Yang D.C., Li D., Quan L.H. Biotransformation of gypenoside XVII to compound K by a recombinant &#x3b2;-glucosidase. Biotechnol Lett. 2016;38:1187&#x2013;1193. doi: 10.1007/s10529-016-2094-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10529-016-2094-3</ArticleId><ArticleId IdType="pubmed">27060008</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin K.C., Seo M.J., Oh H.J., Oh D.K. Highly selective hydrolysis for the outer glucose at the C-20 position in ginsenosides by &#x3b2;-glucosidase from Thermus thermophilus and its application to the production of ginsenoside F2 from gypenoside XVII. Biotechnol. Lett. 2014;36:1287&#x2013;1293. doi: 10.1007/s10529-014-1472-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10529-014-1472-y</ArticleId><ArticleId IdType="pubmed">24563303</ArticleId></ArticleIdList></Reference><Reference><Citation>Du X., Xu L., Ma Y., Lu S., Tang K., Qiao X., Liu J., Wang X., Peng X., Jiang C. Herbal inhibitors of SARS-CoV-2 M(pro) effectively ameliorate acute lung injury in mice. IUBMB Life. 2022;74:532&#x2013;542. doi: 10.1002/iub.2616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.2616</ArticleId><ArticleId IdType="pmc">PMC9087564</ArticleId><ArticleId IdType="pubmed">35383402</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D.Y.W., Li Q.Y., Liu J., Efferth T. Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis. Phytomedicine. 2021;80:153337. doi: 10.1016/j.phymed.2020.153337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2020.153337</ArticleId><ArticleId IdType="pmc">PMC7521884</ArticleId><ArticleId IdType="pubmed">33221457</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y., Wang D., Abula S., Hu Y., Zhao X., Huang Y., Liu J., Wu Y., Wang D., Tao Y., et al. The immunological adjuvant activity of gypenosides liposome against Newcastle disease vaccine. Int. J. Biol. Macromol. 2013;60:116&#x2013;121. doi: 10.1016/j.ijbiomac.2013.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2013.05.024</ArticleId><ArticleId IdType="pubmed">23732326</ArticleId></ArticleIdList></Reference><Reference><Citation>Sornpet B., Potha T., Tragoolpua Y., Pringproa K. Antiviral activity of five Asian medicinal pant crude extracts against highly pathogenic H5N1 avian influenza virus. Asian Pac. J. Trop. Med. 2017;10:871&#x2013;876. doi: 10.1016/j.apjtm.2017.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apjtm.2017.08.010</ArticleId><ArticleId IdType="pubmed">29080615</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T.H., Li Y., Razmovski-Naumovski V., Tran V.H., Li G.Q., Duke C.C., Roufogalis B.D. Gypenoside XLIX isolated from Gynostemma pentaphyllum inhibits nuclear factor-kappaB activation via a PPAR-alpha-dependent pathway. J. Biomed. Sci. 2006;13:535&#x2013;548. doi: 10.1007/s11373-006-9076-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11373-006-9076-8</ArticleId><ArticleId IdType="pubmed">16525884</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T.H., Tran V.H., Roufogalis B.D., Li Y. Gypenoside XLIX, a naturally occurring PPAR-alpha activator, inhibits cytokine-induced vascular cell adhesion molecule-1 expression and activity in human endothelial cells. Eur. J. Pharmacol. 2007;565:158&#x2013;165. doi: 10.1016/j.ejphar.2007.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2007.03.013</ArticleId><ArticleId IdType="pubmed">17434475</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T.H., Tran V.H., Roufogalis B.D., Li Y. Gypenoside XLIX, a naturally occurring gynosaponin, PPAR-alpha dependently inhibits LPS-induced tissue factor expression and activity in human THP-1 monocytic cells. Toxicol. Appl. Pharmacol. 2007;218:30&#x2013;36. doi: 10.1016/j.taap.2006.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2006.10.013</ArticleId><ArticleId IdType="pubmed">17141290</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Chen X., Kan M., Yang J., Gong Q., Jin R., Dai Y., Jin J., Zang H. Gypenoside XLIX loaded nanoparticles targeting therapy for renal fibrosis and its mechanism. Eur. J. Pharmacol. 2021;910:174501. doi: 10.1016/j.ejphar.2021.174501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.174501</ArticleId><ArticleId IdType="pubmed">34529980</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Zang H.M., Xing T., Zhang S.F., Li C., Zhang Y., Dong Y.H., Hu X.W., Yu J.T., Wen J.G., et al. Gypenoside XLIX protects against acute kidney injury by suppressing IGFBP7/IGF1R-mediated programmed cell death and inflammation. Phytomedicine. 2021;85:153541. doi: 10.1016/j.phymed.2021.153541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2021.153541</ArticleId><ArticleId IdType="pubmed">33773190</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F., Hu L., Pan R. Novel dammarane-type glycosides from Gynostemma pentaphyllum. Chem. Pharm. Bull. 2004;52:1440&#x2013;1444. doi: 10.1248/cpb.52.1440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/cpb.52.1440</ArticleId><ArticleId IdType="pubmed">15577241</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh K.H., Oh D.K. Production of the rare ginsenosides compound K, compound Y, and compound Mc by a thermostable beta-glycosidase from Sulfolobus acidocaldarius. Biol. Pharm. Bull. 2009;32:1830&#x2013;1835. doi: 10.1248/bpb.32.1830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.32.1830</ArticleId><ArticleId IdType="pubmed">19881292</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H.J., Shin K.C., Oh D.K. Production of ginsenosides Rg1 and Rh1 by hydrolyzing the outer glycoside at the C-6 position in protopanaxatriol-type ginsenosides using &#x3b2;-glucosidase from Pyrococcus furiosus. Biotechnol. Lett. 2014;36:113&#x2013;119. doi: 10.1007/s10529-013-1331-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10529-013-1331-2</ArticleId><ArticleId IdType="pubmed">24078126</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei J., Xie J., Yin R., Zhao L., Ding G., Wang Z., Xiao W. Enzymatic transformation of ginsenoside Rb1 to ginsenoside 20(S)-Rg3 by GH3 &#x3b2;-glucosidase from Thermotoga thermarum DSM 5069T. J. Mol. Catal. B Enzym. 2015;113:104&#x2013;109. doi: 10.1016/j.molcatb.2014.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcatb.2014.12.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Z.Q., Ng Q.Y., Ng J.W.Q., Mahendran V., Alonso S. Recent progress and challenges in drug development to fight hand, foot and mouth disease. Expert. Opin. Drug Discov. 2020;15:359&#x2013;371. doi: 10.1080/17460441.2019.1659241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2019.1659241</ArticleId><ArticleId IdType="pubmed">31470744</ArticleId></ArticleIdList></Reference><Reference><Citation>Tungmunnithum D., Thongboonyou A., Pholboon A., Yangsabai A. Flavonoids and Other Phenolic Compounds from Medicinal Plants for Pharmaceutical and Medical Aspects: An Overview. Medicines. 2018;5:93. doi: 10.3390/medicines5030093.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines5030093</ArticleId><ArticleId IdType="pmc">PMC6165118</ArticleId><ArticleId IdType="pubmed">30149600</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S., Zhou X., Li F., Xu C., Zheng F., Li J., Zhao H., Dai Y., Liu S., Feng Y. Microbial transformation of ginsenoside Rb1, Re and Rg1 and its contribution to the improved anti-inflammatory activity of ginseng. Sci. Rep. 2017;7:138. doi: 10.1038/s41598-017-00262-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-00262-0</ArticleId><ArticleId IdType="pmc">PMC5428039</ArticleId><ArticleId IdType="pubmed">28273939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghose T.K. Measurement of cellulase activities. Pure Appl. Chem. 1987;59:257&#x2013;268. doi: 10.1351/pac198759020257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1351/pac198759020257</ArticleId></ArticleIdList></Reference><Reference><Citation>GL M. Use of dinitrosalicylic acid reagent for determination of reducing sugar. Anal Chem. 1959;31:426&#x2013;428.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>